Browsing by Subject "B-cell neoplasms"
Now showing items 1-1 of 1
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. (Wiley, 2019-02)Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B-cell malignancies. In ibrutinib clinical studies, low-grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We ...